MaxCyte Inc MXCT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if MXCT is a good fit for your portfolio.
News
-
MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024
-
MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)
-
MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance
-
MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results
-
MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences
Trading Information
- Previous Close Price
- $3.63
- Day Range
- $3.61–3.90
- 52-Week Range
- $2.45–5.55
- Bid/Ask
- $3.62 / $3.88
- Market Cap
- $393.61 Mil
- Volume/Avg
- 651,479 / 560,397
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 9.45
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Core
- Total Number of Employees
- 143
- Website
- https://www.maxcyte.com
Comparables
Valuation
|
Metric
|
MXCT
|
PTGX
|
ACLX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.69 | 4.38 | 5.62 |
Price/Sales | 9.45 | 24.16 | 22.72 |
Price/Cash Flow | — | — | — |
Price/Earnings
MXCT
PTGX
ACLX
Financial Strength
|
Metric
|
MXCT
|
PTGX
|
ACLX
|
|---|---|---|---|
Quick Ratio | 9.75 | 16.54 | 5.94 |
Current Ratio | 10.65 | 16.71 | 6.06 |
Interest Coverage | — | — | −23.39 |
Quick Ratio
MXCT
PTGX
ACLX
Profitability
|
Metric
|
MXCT
|
PTGX
|
ACLX
|
|---|---|---|---|
Return on Assets (Normalized) | −8.64% | −16.60% | −6.26% |
Return on Equity (Normalized) | −9.82% | −18.20% | −12.08% |
Return on Invested Capital (Normalized) | −13.21% | −23.45% | −13.11% |
Return on Assets
MXCT
PTGX
ACLX
Medical Devices Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ABT
| Abbott Laboratories | Fpllsnbrg | Wtkjhf | $184.4 Bil | |
SYK
| Stryker Corp | Mlnqdlgdr | Krvb | $125.0 Bil | |
MDT
| Medtronic PLC | Npdhjrncb | Yzctqy | $107.4 Bil | |
BSX
| Boston Scientific Corp | Nwghpcrt | Qtpzcrr | $106.1 Bil | |
EW
| Edwards Lifesciences Corp | Ltjjcyjy | Ytxrkp | $50.8 Bil | |
DXCM
| DexCom Inc | Brrpqstxv | Nggb | $50.4 Bil | |
ZBH
| Zimmer Biomet Holdings Inc | Dpybgmlfyh | Zbwqz | $24.7 Bil | |
PHG
| Koninklijke Philips NV ADR | Zdhpczy | Brhmw | $24.4 Bil | |
ALGN
| Align Technology Inc | Fvbpytc | Zpygxn | $21.3 Bil | |
PODD
| Insulet Corp | Jlxpnzfjx | Blsjfm | $12.0 Bil |